Cannabinoids and multiple sclerosis

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

There is a growing amount of evidence to suggest that cannabis and individual cannabinoids may be effective in suppressing certain symptoms of multiple sclerosis and spinal cord injury, including spasticity and pain. Anecdotal evidence is to be found in newspaper reports and also in responses to questionnaires. Clinical evidence comes from trials, albeit with rather small numbers of patients. These trials have shown that cannabis, Delta(9)-tetrahydrocannabinol, and nabilone can produce objective and/or subjective relief from spasticity, pain, tremor, and nocturia in patients with multiple sclerosis (8 trials) or spinal cord injury (1 trial), The clinical evidence is supported by results from experiments with animal models of multiple sclerosis. Some of these experiments', performed with mice with chronic relapsing experimental allergic encephalomyelitis (CREAE), have provided strong evidence that cannabinoid-induced reductions in tremor and spasticity are mediated by cannabinoid receptors, both CB1 and CB2. Endocannabinoid concentrations are elevated in the brains and spinal cords of CREAE mice with spasticity, and in line with this observation, spasticity exhibited by CREAE mice can be ameliorated by inhibitors of endocannabinoid membrane transport or enzymic hydrolysis. Research is now needed to establish whether increased endocannabinoid production occurs in multiple sclerosis. Future research should also be directed at obtaining more conclusive evidence about the efficacy of cannabis or individual cannabinoids against the signs and symptoms of these disorders, at devising better modes of administration for cannabinoids and at exploring strategies that maximize separation between the sought-after therapeutic effects and the unwanted effects of these drugs, (C) 2002 Elsevier Science Inc. All rights reserved.

Original languageEnglish
Pages (from-to)165-174
Number of pages10
JournalPharmacology & Therapeutics
Volume95
Issue number2
DOIs
Publication statusPublished - Aug 2002

Keywords

  • multiple sclerosis
  • spinal cord injury
  • pain
  • cannabis
  • tetrahydrocannabinol
  • nabilone
  • experimental autoimmune encephalomyelitis
  • inverse agonist
  • CB2 receptors
  • control spasticity
  • adenylate-cyclase
  • urinary-incontincence
  • rat-brain
  • delta-9-tetrahydrocannabinol
  • model
  • pharmacology

Cite this

Cannabinoids and multiple sclerosis. / Pertwee, Roger G.

In: Pharmacology & Therapeutics, Vol. 95, No. 2, 08.2002, p. 165-174.

Research output: Contribution to journalArticle

@article{a4ebd1a38ec149919342cd2be318147f,
title = "Cannabinoids and multiple sclerosis",
abstract = "There is a growing amount of evidence to suggest that cannabis and individual cannabinoids may be effective in suppressing certain symptoms of multiple sclerosis and spinal cord injury, including spasticity and pain. Anecdotal evidence is to be found in newspaper reports and also in responses to questionnaires. Clinical evidence comes from trials, albeit with rather small numbers of patients. These trials have shown that cannabis, Delta(9)-tetrahydrocannabinol, and nabilone can produce objective and/or subjective relief from spasticity, pain, tremor, and nocturia in patients with multiple sclerosis (8 trials) or spinal cord injury (1 trial), The clinical evidence is supported by results from experiments with animal models of multiple sclerosis. Some of these experiments', performed with mice with chronic relapsing experimental allergic encephalomyelitis (CREAE), have provided strong evidence that cannabinoid-induced reductions in tremor and spasticity are mediated by cannabinoid receptors, both CB1 and CB2. Endocannabinoid concentrations are elevated in the brains and spinal cords of CREAE mice with spasticity, and in line with this observation, spasticity exhibited by CREAE mice can be ameliorated by inhibitors of endocannabinoid membrane transport or enzymic hydrolysis. Research is now needed to establish whether increased endocannabinoid production occurs in multiple sclerosis. Future research should also be directed at obtaining more conclusive evidence about the efficacy of cannabis or individual cannabinoids against the signs and symptoms of these disorders, at devising better modes of administration for cannabinoids and at exploring strategies that maximize separation between the sought-after therapeutic effects and the unwanted effects of these drugs, (C) 2002 Elsevier Science Inc. All rights reserved.",
keywords = "multiple sclerosis, spinal cord injury, pain, cannabis, tetrahydrocannabinol, nabilone, experimental autoimmune encephalomyelitis, inverse agonist, CB2 receptors , control spasticity, adenylate-cyclase, urinary-incontincence, rat-brain, delta-9-tetrahydrocannabinol, model, pharmacology",
author = "Pertwee, {Roger G}",
year = "2002",
month = "8",
doi = "10.1016/S0163-7258(02)00255-3",
language = "English",
volume = "95",
pages = "165--174",
journal = "Pharmacology & Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Cannabinoids and multiple sclerosis

AU - Pertwee, Roger G

PY - 2002/8

Y1 - 2002/8

N2 - There is a growing amount of evidence to suggest that cannabis and individual cannabinoids may be effective in suppressing certain symptoms of multiple sclerosis and spinal cord injury, including spasticity and pain. Anecdotal evidence is to be found in newspaper reports and also in responses to questionnaires. Clinical evidence comes from trials, albeit with rather small numbers of patients. These trials have shown that cannabis, Delta(9)-tetrahydrocannabinol, and nabilone can produce objective and/or subjective relief from spasticity, pain, tremor, and nocturia in patients with multiple sclerosis (8 trials) or spinal cord injury (1 trial), The clinical evidence is supported by results from experiments with animal models of multiple sclerosis. Some of these experiments', performed with mice with chronic relapsing experimental allergic encephalomyelitis (CREAE), have provided strong evidence that cannabinoid-induced reductions in tremor and spasticity are mediated by cannabinoid receptors, both CB1 and CB2. Endocannabinoid concentrations are elevated in the brains and spinal cords of CREAE mice with spasticity, and in line with this observation, spasticity exhibited by CREAE mice can be ameliorated by inhibitors of endocannabinoid membrane transport or enzymic hydrolysis. Research is now needed to establish whether increased endocannabinoid production occurs in multiple sclerosis. Future research should also be directed at obtaining more conclusive evidence about the efficacy of cannabis or individual cannabinoids against the signs and symptoms of these disorders, at devising better modes of administration for cannabinoids and at exploring strategies that maximize separation between the sought-after therapeutic effects and the unwanted effects of these drugs, (C) 2002 Elsevier Science Inc. All rights reserved.

AB - There is a growing amount of evidence to suggest that cannabis and individual cannabinoids may be effective in suppressing certain symptoms of multiple sclerosis and spinal cord injury, including spasticity and pain. Anecdotal evidence is to be found in newspaper reports and also in responses to questionnaires. Clinical evidence comes from trials, albeit with rather small numbers of patients. These trials have shown that cannabis, Delta(9)-tetrahydrocannabinol, and nabilone can produce objective and/or subjective relief from spasticity, pain, tremor, and nocturia in patients with multiple sclerosis (8 trials) or spinal cord injury (1 trial), The clinical evidence is supported by results from experiments with animal models of multiple sclerosis. Some of these experiments', performed with mice with chronic relapsing experimental allergic encephalomyelitis (CREAE), have provided strong evidence that cannabinoid-induced reductions in tremor and spasticity are mediated by cannabinoid receptors, both CB1 and CB2. Endocannabinoid concentrations are elevated in the brains and spinal cords of CREAE mice with spasticity, and in line with this observation, spasticity exhibited by CREAE mice can be ameliorated by inhibitors of endocannabinoid membrane transport or enzymic hydrolysis. Research is now needed to establish whether increased endocannabinoid production occurs in multiple sclerosis. Future research should also be directed at obtaining more conclusive evidence about the efficacy of cannabis or individual cannabinoids against the signs and symptoms of these disorders, at devising better modes of administration for cannabinoids and at exploring strategies that maximize separation between the sought-after therapeutic effects and the unwanted effects of these drugs, (C) 2002 Elsevier Science Inc. All rights reserved.

KW - multiple sclerosis

KW - spinal cord injury

KW - pain

KW - cannabis

KW - tetrahydrocannabinol

KW - nabilone

KW - experimental autoimmune encephalomyelitis

KW - inverse agonist

KW - CB2 receptors

KW - control spasticity

KW - adenylate-cyclase

KW - urinary-incontincence

KW - rat-brain

KW - delta-9-tetrahydrocannabinol

KW - model

KW - pharmacology

U2 - 10.1016/S0163-7258(02)00255-3

DO - 10.1016/S0163-7258(02)00255-3

M3 - Article

VL - 95

SP - 165

EP - 174

JO - Pharmacology & Therapeutics

JF - Pharmacology & Therapeutics

SN - 0163-7258

IS - 2

ER -